A Simple and Rapid LC-MS/MS Method for Therapeutic Drug Monitoring of Lenalidomide
Immunomodulatory drugs lenalidomide (LENA) and pomalidomide (POMA) are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. LENA is used as a treatment for myeloma and blood disorders called myelodysplastic syndromes. The...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
National Centre of Excellence in Analytical Chemsitry
2020-06-01
|
Series: | Pakistan Journal of Analytical & Environmental Chemistry |
Subjects: | |
Online Access: | http://www.pjaec.pk/index.php/pjaec/article/view/542/313 |
id |
doaj-dca9e32d06f84c49b09568f33ea3978d |
---|---|
record_format |
Article |
spelling |
doaj-dca9e32d06f84c49b09568f33ea3978d2020-11-25T03:04:33ZengNational Centre of Excellence in Analytical ChemsitryPakistan Journal of Analytical & Environmental Chemistry1996-918X2221-52552020-06-01211192610.21743/pjaec/2020.06.03A Simple and Rapid LC-MS/MS Method for Therapeutic Drug Monitoring of LenalidomideNeşet Neşetoğlu0Cem Kaplan1Serap Sağlık Aslan 2Durişehvar Özer Ünal3Faculty of Pharmacy, Department of Analytical Chemistry, Drug Research Center, Beyazıt, 34116, İstanbul, Turkey.Faculty of Pharmacy, Department of Analytical Chemistry, Drug Research Center, Beyazıt, 34116, İstanbul, Turkey.Faculty of Pharmacy, Department of Analytical Chemistry, Drug Research Center, Beyazıt, 34116, İstanbul, Turkey.Faculty of Pharmacy, Department of Analytical Chemistry, Drug Research Center, Beyazıt, 34116, İstanbul, Turkey.Immunomodulatory drugs lenalidomide (LENA) and pomalidomide (POMA) are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. LENA is used as a treatment for myeloma and blood disorders called myelodysplastic syndromes. The maximum clinical dose of LENA for some haematological cancers is generally ≤25 mg. Therapeutic drug monitoring (TDM) is important for the individualization of drug dosage. A highly sensitive and high performance liquid chromatography tandem mass spectrometry (LC–MS/MS) assay was developed and validated for the quantification of LENA in human plasma. LENA was extracted from human plasma by liquid-liquid extraction by ethyl acetate and analysed using a reversed phase isocratic elution on a Poroshell 120 EC-C18, (4.6 - 50 mm, 2.7µm) column. 0.1% formic acid: methanol (10:90% v/v), was used as mobile phase and detection was performed by triple quadrupole mass spectrometry LC-MS/MS using jet stream electrospray ionization in negative mode. POMA was used as the internal standard (IS). Analyte and IS were detected by tandem mass spectrometry using multiple reaction monitoring (MRM) of precursor–product ion transitions with 0.100 s dwell time, at m/z 258.0 > 213.0 for LENA and m/z 272.0 > 161.0 for POMA. The calibration curves were consistently accurate and precise over the concentration range of 20 ng/mL to 1000 ng/mL in plasma for LENA. This novel LC–MS/MS method competes with all the regulatory requirements and shows satisfactory accuracy and precision. It is sufficiently sensitive for the performance of pharmacokinetic, bioequivalence and TDM studies in humans.http://www.pjaec.pk/index.php/pjaec/article/view/542/313lenalidomidelc-ms/ms |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Neşet Neşetoğlu Cem Kaplan Serap Sağlık Aslan Durişehvar Özer Ünal |
spellingShingle |
Neşet Neşetoğlu Cem Kaplan Serap Sağlık Aslan Durişehvar Özer Ünal A Simple and Rapid LC-MS/MS Method for Therapeutic Drug Monitoring of Lenalidomide Pakistan Journal of Analytical & Environmental Chemistry lenalidomide lc-ms/ms |
author_facet |
Neşet Neşetoğlu Cem Kaplan Serap Sağlık Aslan Durişehvar Özer Ünal |
author_sort |
Neşet Neşetoğlu |
title |
A Simple and Rapid LC-MS/MS Method for Therapeutic Drug Monitoring of Lenalidomide |
title_short |
A Simple and Rapid LC-MS/MS Method for Therapeutic Drug Monitoring of Lenalidomide |
title_full |
A Simple and Rapid LC-MS/MS Method for Therapeutic Drug Monitoring of Lenalidomide |
title_fullStr |
A Simple and Rapid LC-MS/MS Method for Therapeutic Drug Monitoring of Lenalidomide |
title_full_unstemmed |
A Simple and Rapid LC-MS/MS Method for Therapeutic Drug Monitoring of Lenalidomide |
title_sort |
simple and rapid lc-ms/ms method for therapeutic drug monitoring of lenalidomide |
publisher |
National Centre of Excellence in Analytical Chemsitry |
series |
Pakistan Journal of Analytical & Environmental Chemistry |
issn |
1996-918X 2221-5255 |
publishDate |
2020-06-01 |
description |
Immunomodulatory drugs lenalidomide (LENA) and pomalidomide (POMA) are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. LENA is used as a treatment for myeloma and blood disorders called myelodysplastic syndromes. The maximum clinical dose of LENA for some haematological cancers is generally ≤25 mg. Therapeutic drug monitoring (TDM) is important for the individualization of drug dosage. A highly sensitive and high performance liquid chromatography tandem mass spectrometry (LC–MS/MS) assay was developed and validated for the quantification of LENA in human plasma. LENA was extracted from human plasma by liquid-liquid extraction by ethyl acetate and analysed using a reversed phase isocratic elution on a Poroshell 120 EC-C18, (4.6 - 50 mm, 2.7µm) column. 0.1% formic acid: methanol (10:90% v/v), was used as mobile phase and detection was performed by triple quadrupole mass spectrometry LC-MS/MS using jet stream electrospray ionization in negative mode. POMA was used as the internal standard (IS). Analyte and IS were detected by tandem mass spectrometry using multiple reaction monitoring (MRM) of precursor–product ion transitions with 0.100 s dwell time, at m/z 258.0 > 213.0 for LENA and m/z 272.0 > 161.0 for POMA. The calibration curves were consistently accurate and precise over the concentration range of 20 ng/mL to 1000 ng/mL in plasma for LENA. This novel LC–MS/MS method competes with all the regulatory requirements and shows satisfactory accuracy and precision. It is sufficiently sensitive for the performance of pharmacokinetic, bioequivalence and TDM studies in humans. |
topic |
lenalidomide lc-ms/ms |
url |
http://www.pjaec.pk/index.php/pjaec/article/view/542/313 |
work_keys_str_mv |
AT nesetnesetoglu asimpleandrapidlcmsmsmethodfortherapeuticdrugmonitoringoflenalidomide AT cemkaplan asimpleandrapidlcmsmsmethodfortherapeuticdrugmonitoringoflenalidomide AT serapsaglıkaslan asimpleandrapidlcmsmsmethodfortherapeuticdrugmonitoringoflenalidomide AT durisehvarozerunal asimpleandrapidlcmsmsmethodfortherapeuticdrugmonitoringoflenalidomide AT nesetnesetoglu simpleandrapidlcmsmsmethodfortherapeuticdrugmonitoringoflenalidomide AT cemkaplan simpleandrapidlcmsmsmethodfortherapeuticdrugmonitoringoflenalidomide AT serapsaglıkaslan simpleandrapidlcmsmsmethodfortherapeuticdrugmonitoringoflenalidomide AT durisehvarozerunal simpleandrapidlcmsmsmethodfortherapeuticdrugmonitoringoflenalidomide |
_version_ |
1724681149970644992 |